BridgeBio Pharma, Inc. BBIO
Super Investor & Insider
2
Fondi che lo detengono
#419
Rank consenso
2.9%
% dei portafogli
$882.8M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 2.46% | Reduce 17.73% | 11,842,434 | $879.4M |
| Polen Capital Management · Polen Capital Management | 0.02% | Add 20.12% | 45,934 | $3.4M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers. The company concentrates on conditions with well-defined genetic causes, aiming to design targeted therapies that address the underlying molec…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees834
TickerBBIO
Statistics
Market Cap$13.23B
Revenue (TTM)$502.1M
Net Income-$732.9M
Net Margin-146.0%
EPS$-3.78
P/E-17.79
P/S22.81
P/B-5.77
EV/EBITDA-29.65
ROE34.9%
Dividend Yield—
Price$67.58
Data: Twelve Data · Revenue = mcap / P/S